Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX)

Historical Holders from Q1 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
EWTX on Nasdaq
Shares outstanding
105,337,747
Price per share
$24.82
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
111,964,031
Holdings value
$1,816,272,346
% of all portfolios
0%
Share change
-6,779,934
Value change
-$102,065,519
Average buys %
+0%
Average sells %
-0%
Number of holders
171
Price from insider filings
$21.12
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 14% $174,187,741 15,252,867 ORBIMED ADVISORS LLC 09 May 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $169,149,248 10,428,437 RA Capital Management, L.P. 30 Sep 2025
BAKER BROS. ADVISORS LP 6.9% $107,032,021 7,305,940 Baker Bros. Advisors LP 30 Jun 2025
BlackRock, Inc. 5.5% $89,702,936 5,824,866 BlackRock, Inc. 30 Jun 2025
JANUS HENDERSON GROUP PLC 4.7% -10% $80,764,749 -$8,499,572 4,979,331 -9.5% JANUS HENDERSON GROUP PLC 30 Sep 2025
Paradigm Biocapital Advisors LP 5% $54,118,569 4,738,929 Paradigm BioCapital Advisors LP 27 Jan 2025
PERCEPTIVE ADVISORS LLC 4.4% -28% $67,975,253 -$25,719,496 4,639,949 -27% Perceptive Advisors LLC 30 Jun 2025
As of 30 Sep 2025, Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) has 171 institutional shareholders filing 13F forms. They hold 111,964,031 shares .

Top 25 institutional shareholders own 92% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 15% 15,518,492 0% 6% $251,709,940
RA CAPITAL MANAGEMENT, L.P. 9.9% 10,428,437 +5.3% 2.1% $169,149,248
BAKER BROS. ADVISORS LP 6.9% 7,305,940 0% 0.86% $118,502,347
BlackRock, Inc. 6% 6,351,487 -6.3% 0% $103,021,118
Paradigm Biocapital Advisors LP 5.9% 6,170,131 +0.45% 3% $100,079,525
NOVO HOLDINGS A/S 5.1% 5,350,000 0% 5.6% $86,777,000
BRAIDWELL LP 4.9% 5,210,831 0% 2.5% $84,519,679
JANUS HENDERSON GROUP PLC 4.7% 4,979,331 -9.5% 0.04% $80,804,202
VANGUARD GROUP INC 4.6% 4,803,941 -0.78% 0% $77,919,924
Cormorant Asset Management, LP 3.8% 4,010,000 -5.7% 4.5% $65,042,200
Siren, L.L.C. 3.7% 3,897,099 +23% 2.5% $63,210,946
PERCEPTIVE ADVISORS LLC 3.6% 3,795,894 -18% 1.8% $61,569,401
Bellevue Group AG 2.6% 2,775,997 0% 0.94% $45,026,671
Driehaus Capital Management LLC 2.1% 2,228,285 +6% 0.26% $36,142,783
MPM BIOIMPACT LLC 1.6% 1,720,741 0% 4.6% $27,910,419
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,717,641 -4.4% 0% $27,864,280
STATE STREET CORP 1.6% 1,699,909 -4.6% 0% $27,572,524
Integral Health Asset Management, LLC 1.4% 1,500,000 +50% 1.8% $24,330,000
First Light Asset Management, LLC 1.3% 1,414,994 -17% 2.2% $22,951,203
DIMENSIONAL FUND ADVISORS LP 1.1% 1,183,136 +13% 0% $19,187,177
AMERICAN CENTURY COMPANIES INC 1% 1,095,473 +40% 0.01% $17,768,606
New Leaf Venture Partners, L.L.C. 0.98% 1,030,161 0% 39% $16,709,211
MORGAN STANLEY 0.83% 869,678 +20% 0% $14,106,178
DEERFIELD MANAGEMENT COMPANY, L.P. 0.73% 765,694 -63% 0.19% $12,419,557
MILLENNIUM MANAGEMENT LLC 0.69% 725,425 -21% 0.01% $11,766,394

Institutional Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 90,466 $2,245,253 +$1,960,387 $24.82 4
2025 Q3 111,964,031 $1,816,272,346 -$102,065,519 $16.22 171
2025 Q2 118,737,861 $1,557,153,070 +$135,315,941 $13.11 177
2025 Q1 105,289,941 $2,320,227,306 +$130,326,521 $22.00 190
2024 Q4 98,906,508 $2,640,403,916 -$77,587,352 $26.70 196
2024 Q3 101,228,729 $2,702,243,259 -$13,752,009 $26.69 175
2024 Q2 101,619,838 $1,830,140,578 +$179,064,439 $18.01 138
2024 Q1 91,599,596 $1,670,726,546 +$308,746,097 $18.24 125
2023 Q4 65,285 $714,218 +$379,387 $10.94 2
2023 Q3 68,414,581 $392,036,024 -$8,244,254 $5.73 83
2023 Q2 69,476,300 $538,657,783 +$23,688,287 $7.75 93
2023 Q1 66,455,672 $443,090,043 -$749,264 $6.67 85
2022 Q4 66,449,117 $594,049,993 +$17,695,612 $8.94 88
2022 Q3 64,378,877 $633,490,366 +$132,531,110 $9.84 90
2022 Q2 48,863,869 $388,956,841 -$30,414,127 $7.96 72
2022 Q1 52,530,925 $509,616,727 +$35,074,105 $9.70 68
2021 Q4 50,239,434 $767,640,710 +$33,441,775 $15.28 56
2021 Q3 48,038,152 $795,758,000 +$3,108,225 $16.60 47
2021 Q2 47,877,175 $1,028,333,000 +$40,348,400 $21.33 46
2021 Q1 45,681,359 $1,477,378,000 +$1,477,378,518 $32.50 31